Do analysts rate RNAC or XBIT?

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 202.55%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer RNAC or XBIT?

In the previous week, Cartesian Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Cartesian Therapeutics' score of -0.38 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FATE or XBIT?

Fate Therapeutics currently has a consensus price target of $5.13, suggesting a potential upside of 70.49%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to FATE or XBIT?

In the previous week, Fate Therapeutics had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Fate Therapeutics' score of 0.47 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend IVVD or XBIT?

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 812.20%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts clearly believe Invivyd is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IVVD or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. XBiotech's return on equity of -26.10% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% XBiotech N/A -26.10% -25.06%

Does the media favor IVVD or XBIT?

In the previous week, Invivyd had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Invivyd and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Invivyd's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XBIT or ACIU?

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 208.13%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is XBIT or ACIU more profitable?

XBiotech has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. XBiotech's return on equity of -26.10% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% AC Immune -1,788.02% -125.26% -40.85%

Does the media refer more to XBIT or ACIU?

In the previous week, AC Immune had 4 more articles in the media than XBiotech. MarketBeat recorded 6 mentions for AC Immune and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat AC Immune's score of 1.12 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NAGE or XBIT?

Niagen Bioscience presently has a consensus target price of $10.50, suggesting a potential upside of 205.77%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

XBiotech (XBIT) Competitors

$2.31 +0.01 (+0.22%)

As of 12:10 PM Eastern

Compare

XBIT vs. RNAC, FATE, IVVD, ACIU, and NAGE

Should you buy XBiotech stock or one of its competitors? MarketBeat compares XBiotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XBiotech include Cartesian Therapeutics (RNAC), Fate Therapeutics (FATE), Invivyd (IVVD), AC Immune (ACIU), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry.

How does XBiotech compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

XBiotech has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$1.78M	178.36	-$130.30M	-$5.90	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 202.55%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

XBiotech has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
XBiotech	N/A	-26.10%	-25.06%

Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, Cartesian Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Cartesian Therapeutics' score of -0.38 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cartesian Therapeutics beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fate Therapeutics currently has a consensus price target of $5.13, suggesting a potential upside of 70.49%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XBiotech has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. XBiotech's return on equity of -26.10% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
XBiotech	N/A	-26.10%	-25.06%

Fate Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

In the previous week, Fate Therapeutics had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Fate Therapeutics' score of 0.47 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XBiotech has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.32M	55.47	-$136.32M	-$1.09	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Summary

Fate Therapeutics beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Invivyd?

Invivyd (NASDAQ:IVVD) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 812.20%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts clearly believe Invivyd is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

XBiotech has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.84	-$52.49M	-$0.31	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

XBiotech has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. XBiotech's return on equity of -26.10% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
XBiotech	N/A	-26.10%	-25.06%

In the previous week, Invivyd had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Invivyd and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat Invivyd's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Summary

XBiotech beats Invivyd on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to AC Immune?

XBiotech (NASDAQ:XBIT) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

XBiotech has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
AC Immune	$3.70M	66.91	-$85.03M	-$0.82	N/A

55.7% of XBiotech shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 208.13%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

XBiotech has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. XBiotech's return on equity of -26.10% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
AC Immune	-1,788.02%	-125.26%	-40.85%

In the previous week, AC Immune had 4 more articles in the media than XBiotech. MarketBeat recorded 6 mentions for AC Immune and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.27 beat AC Immune's score of 1.12 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

XBiotech beats AC Immune on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, XBiotech had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.87 beat XBiotech's score of 1.27 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Very Positive
XBiotech	Positive

Niagen Bioscience has a net margin of 14.29% compared to XBiotech's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
XBiotech	N/A	-26.10%	-25.06%

Niagen Bioscience presently has a consensus target price of $10.50, suggesting a potential upside of 205.77%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Niagen Bioscience has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Niagen Bioscience has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.10	$17.38M	$0.21	16.35
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Summary

Niagen Bioscience beats XBiotech on 12 of the 15 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.28M	$3.73B	$6.93B	$12.40B
Dividend Yield	N/A	2.21%	2.66%	6.14%
P/E Ratio	-1.75	21.72	27.65	25.03
Price / Sales	N/A	339.16	536.21	100.69
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	0.50	8.66	10.96	6.53
Net Income	-$45.54M	$23.81M	$3.56B	$336.59M
7 Day Performance	-1.07%	5.41%	3.59%	2.90%
1 Month Performance	-4.36%	7.90%	4.37%	0.58%
1 Year Performance	-28.42%	63.77%	35.37%	26.37%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.7319 of 5 stars	$2.31 +0.2%	N/A	-27.4%	$70.28M	N/A	N/A	100	News Coverage Positive News Analyst Downgrade
RNAC Cartesian Therapeutics	3.8355 of 5 stars	$10.42 +8.1%	$32.60 +212.9%	-6.5%	$283.24M	$2.80M	N/A	64	News Coverage Analyst Downgrade
FATE Fate Therapeutics	2.9959 of 5 stars	$2.70 +11.6%	$5.13 +89.8%	+164.9%	$282.07M	$6.65M	N/A	550	News Coverage
IVVD Invivyd	3.0583 of 5 stars	$0.87 -7.6%	$8.00 +817.0%	+18.5%	$278.02M	$53.43M	N/A	100
ACIU AC Immune	3.1565 of 5 stars	$2.38 -10.5%	$7.50 +215.1%	+20.2%	$270.72M	$4.31M	N/A	140	News Coverage Positive News Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. RNAC, FATE, IVVD, ACIU, and NAGE

How does XBiotech compare to Cartesian Therapeutics?

Summary

How does XBiotech compare to Fate Therapeutics?

Summary

How does XBiotech compare to Invivyd?

Summary

How does XBiotech compare to AC Immune?

Summary

How does XBiotech compare to Niagen Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. RNAC, FATE, IVVD, ACIU, and NAGE

How does XBiotech compare to Cartesian Therapeutics?

Which has preferable earnings and valuation, RNAC or XBIT?

Do analysts rate RNAC or XBIT?

Do institutionals and insiders have more ownership in RNAC or XBIT?

Is RNAC or XBIT more profitable?

Which has more risk & volatility, RNAC or XBIT?

Does the media prefer RNAC or XBIT?

Summary

How does XBiotech compare to Fate Therapeutics?

Do insiders & institutionals hold more shares of FATE or XBIT?

Do analysts prefer FATE or XBIT?

Is FATE or XBIT more profitable?

Which has more risk & volatility, FATE or XBIT?

Does the media refer more to FATE or XBIT?

Which has higher earnings and valuation, FATE or XBIT?

Summary

How does XBiotech compare to Invivyd?

Do analysts recommend IVVD or XBIT?

Do institutionals & insiders have more ownership in IVVD or XBIT?

Which has preferable earnings and valuation, IVVD or XBIT?

Is IVVD or XBIT more profitable?

Does the media favor IVVD or XBIT?

Which has more volatility & risk, IVVD or XBIT?

Summary

How does XBiotech compare to AC Immune?

Which has more volatility and risk, XBIT or ACIU?

Which has stronger earnings & valuation, XBIT or ACIU?

Do institutionals and insiders have more ownership in XBIT or ACIU?

Do analysts recommend XBIT or ACIU?

Is XBIT or ACIU more profitable?

Does the media refer more to XBIT or ACIU?

Summary

How does XBiotech compare to Niagen Bioscience?

Does the media prefer NAGE or XBIT?

Is NAGE or XBIT more profitable?

Do analysts recommend NAGE or XBIT?

Do insiders & institutionals hold more shares of NAGE or XBIT?

Which has more volatility & risk, NAGE or XBIT?

Which has stronger valuation and earnings, NAGE or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools